1 of 1

Fresolimumab

Catalogue No.:abx831087

Fresolimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TGFB/TGF beta, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.

Target:	TGFB/TGF beta
Clonality:	Monoclonal
Reactivity:	Human
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions:	Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
Isotype:	IgG4 Kappa
Form:	Liquid
Purity:	> 95%
Purification:	Purified from cell culture supernatants by Protein A/G chromatography.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer:	0.01 M PBS. pH 7.4.
CAS Number:	948564-73-6
Concentration:	Batch-dependent, typically between 0.5-2.0 mg/ml.
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
v1.0.0	Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951 Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413 Abbexa BV, Leiden, NL Website: www.abbexa.com · Email: info@abbexa.com